Pancreatic Neuroendocrine Tumor Clinical Trials in Nashville, Tennessee
7 recruitingNashville, Tennessee
Showing 1–7 of 7 trials
Recruiting
Phase 1
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
Solid TumorNeuroendocrine TumorsGep Net+6 more
RayzeBio, Inc.104 enrolled9 locationsNCT07165132
Recruiting
Phase 2
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Pancreatic Neuroendocrine TumorVon Hippel-Lindau DiseasePheochromocytoma/Paraganglioma+2 more
Merck Sharp & Dohme LLC355 enrolled84 locationsNCT04924075
Recruiting
Phase 1Phase 2
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
ParagangliomaPheochromocytomaMeningioma+4 more
Perspective Therapeutics300 enrolled19 locationsNCT05636618
Recruiting
Phase 3
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
Somatostatin Receptor Positive (SSTR+)Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Novartis Pharmaceuticals240 enrolled65 locationsNCT06784752
Recruiting
Phase 2Phase 3
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Pancreatic Neuroendocrine Tumor (pNET)Extra-Pancreatic Neuroendocrine Tumor (epNET)
Exelixis440 enrolled80 locationsNCT06943755
Recruiting
Phase 3
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
Neuroendocrine TumorsGep NetCarcinoid Tumor+4 more
RayzeBio, Inc.338 enrolled54 locationsNCT05477576
Recruiting
Phase 4
Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors
Metastatic Malignant Neoplasm in the LiverDigestive System Neuroendocrine Tumor G1Digestive System Neuroendocrine Tumor G2+3 more
Vanderbilt-Ingram Cancer Center6 enrolled1 locationNCT06016855